unexpect
outbreak
middl
east
respiratori
syndrom
coronaviru
merscov
infect
occur
may
juli
south
korea
although
role
antivir
treatment
mer
definit
proven
antivir
treatment
may
consid
addit
appropri
support
care
mer
combin
regimen
type
interferon
ribavirin
lopinavirritonavir
recommend
antivir
treatment
mer
yet
unknown
whether
antivir
treatment
mer
could
affect
product
persist
neutral
antibodi
time
evalu
neutral
activ
serum
three
patient
year
recoveri
merscov
infect
associ
mild
pneumonia
treat
antivir
mer
outbreak
south
korea
three
individu
year
success
recov
merscov
infect
without
complic
enrol
studi
total
ml
blood
collect
acid
citrat
dextros
tube
patient
studi
approv
institut
review
board
irb
sever
hospit
studi
conduct
complianc
local
irb
guidelin
particip
written
inform
consent
merscov
pseudoviru
gener
western
blot
perform
detect
merscov
protein
pseudoviru
gener
previous
describ
modif
briefli
cell
atcc
manassa
va
usa
cotransfect
recombin
merscov
plasmid
contain
fulllength
protein
sino
biolog
inc
wayn
pa
usa
plasmid
encod
envdefect
luciferas
express
aid
reagent
program
nation
institut
health
tissu
cultur
flask
use
calcium
phosphat
method
cell
chang
fresh
dulbecco
modifi
eagl
medium
hour
later
supernat
harvest
posttransfect
use
sourc
pseudovirus
singlecycl
infect
pseudoviru
inhibit
assay
establish
detect
neutral
activ
patient
sera
pseudoviruscontain
supernat
incub
serial
dilut
patient
serum
hour
addit
target
cell
vero
cell
preplat
cultur
plate
cellswel
media
replac
hour
follow
lysi
cell
hour
later
use
cell
lysi
buffer
perkinelm
waltham
usa
lysat
transfer
luminomet
plate
luciferas
substrat
perkinelm
ad
plate
rel
luciferas
activ
determin
inhibit
merscov
pseudoviru
present
percentag
inhibit
rel
light
unit
rlu
control
serum
collect
healthi
volunt
subject
man
diagnos
merscov
infect
real
time
polymeras
chain
reaction
pcr
nasopharyng
aspir
june
ambul
driver
expos
merscov
infect
patient
patient
transfer
june
symptom
includ
fever
myalgia
headach
appear
june
cough
sputum
product
dyspnea
respiratori
symptom
chest
radiographi
perform
june
show
pneumon
consolid
right
lower
lung
field
treat
combin
ribavirin
mg
load
follow
mg
everi
hour
day
mg
everi
hour
lopinavirritonavir
mg
oral
everi
hour
june
repeat
merscov
pcr
test
show
neg
result
june
full
recoveri
achiev
without
complic
blood
sampl
collect
juli
subject
woman
diagnos
merscov
infect
june
indirectli
expos
merscov
may
anoth
hospit
merscov
infect
diagnos
multib
room
diarrhea
commenc
day
prior
diagnosi
fever
myalgia
sore
throat
cough
sputum
product
mild
dyspnea
commenc
day
diagnosi
chest
radiographi
show
peribronchi
pneumon
consolid
right
middl
lung
field
june
patient
treat
combin
ribavirin
lopinavirritonavir
june
lopinavirritonavir
discontinu
ribavirin
dose
reduc
mgkg
everi
hour
due
jaundic
two
consecut
neg
result
merscov
pcr
confirm
june
full
recoveri
achiev
without
complic
blood
sampl
collect
juli
subject
man
diagnos
merscov
infect
june
expos
merscov
infect
patient
june
high
fever
myalgia
cough
commenc
june
chest
radiographi
show
pneumon
consolid
left
middl
right
lower
lung
field
treat
combin
ribavirin
lopinavirritonavir
june
two
consecut
neg
result
merscov
pcr
confirm
june
fever
subsid
day
initi
treatment
associ
improv
chest
radiographi
full
recoveri
achiev
without
complic
blood
sampl
collect
septemb
subject
underli
comorbid
western
blot
identifi
incorpor
merscov
protein
packag
merscov
pseudoviru
show
clear
band
correspond
merscov
protein
shown
fig
threefold
dilut
serum
subject
show
reduct
rlu
respect
subject
show
reduct
find
studi
inconsist
previou
observ
previou
studi
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
found
patient
igg
posit
postsymptom
onset
respect
howev
year
later
popul
sarscov
specif
igg
studi
antibodi
merscov
includ
neutral
antibodi
show
antibodi
persist
six
seven
individu
month
merscov
outbreak
jordan
seven
subject
respiratori
symptom
underli
diseas
five
substanti
pneumonia
mild
asymptomat
merscov
infect
could
potenti
associ
develop
lower
level
merscov
neutral
antibodi
time
patient
studi
might
treat
antivir
subject
studi
also
young
healthi
mild
pneumon
consolid
admiss
moreov
patient
studi
treat
ribavirin
lopinavirritonavir
antivir
treatment
mer
associ
mild
pneumonia
might
decreas
viral
replic
reduc
antibodi
respons
earli
stage
diseas
result
identifi
lowlevel
neutral
activ
within
convalesc
serum
small
number
subject
import
limit
studi
furthermor
could
evalu
pair
sera
compar
earli
stage
ill
postrecoveri
viral
load
earli
infect
time
may
associ
neutral
antibodi
diseas
outcom
could
collect
data
viral
load
subject
addit
could
valid
pseudoviru
inhibit
assay
posit
control
subject
without
treatment
could
enrol
comparison
conclus
neutral
activ
demonstr
sera
three
patient
mild
pneumonia
year
success
treat
antivir
agent
recov
merscov
infect
